Compounds > quinoxalines
Page last updated: 2024-08-17

quinoxalines and Waldenstrom Macroglobulinemia

quinoxalines has been researched along with Waldenstrom Macroglobulinemia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Al-Katib, AM; Dandashi, MH; Mensah-Osman, EJ; Mohammad, RM1
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM; Osman, NI; Wu, HY1
Al-Katib, A; Dandashi, M; Mensah-Osman, E; Mohammad, R1
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM1

Other Studies

4 other study(ies) available for quinoxalines and Waldenstrom Macroglobulinemia

ArticleYear
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:14

    Topics: Animals; Blotting, Western; Cell Division; Disease Models, Animal; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Quinoxalines; Time Factors; Topoisomerase II Inhibitors; Waldenstrom Macroglobulinemia

2002
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:14

    Topics: Antigens, Neoplasm; Blotting, Western; Culture Media, Serum-Free; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Transplantation; Protein Isoforms; Quinoxalines; Time Factors; Tumor Cells, Cultured; Up-Regulation; Waldenstrom Macroglobulinemia

2002
XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
    International journal of oncology, 2003, Volume: 23, Issue:6

    Topics: Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclosporine; Cytochromes c; Cytosol; Densitometry; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electron Transport Complex IV; Enzyme Activation; Enzyme Inhibitors; Fas Ligand Protein; Fluorometry; Humans; Ligands; Membrane Glycoproteins; Mitochondria; Models, Biological; Poly(ADP-ribose) Polymerases; Quinoxalines; Signal Transduction; Time Factors; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Up-Regulation; Waldenstrom Macroglobulinemia

2003
Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15

    Topics: Animals; Cell Division; Etoposide; Humans; Mice; Mice, SCID; Quinoxalines; Transplantation, Heterologous; Waldenstrom Macroglobulinemia

2003